Holen Sie sich die Stockscreener-App
1.65
2.94%
-0.05
Schlusskurs vom Vortag:
$1.70
Offen:
$1.71
24-Stunden-Volumen:
231.73K
Relative Volume:
0.18
Marktkapitalisierung:
$103.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.52M
KGV:
-0.927
EPS:
-1.78
Netto-Cashflow:
$-107.56M
1W Leistung:
+19.57%
1M Leistung:
+30.95%
6M Leistung:
+52.78%
1J Leistung:
+70.10%
1-Tages-Spanne:
$1.62
$1.718
1-Wochen-Bereich:
$1.34
$1.718
52-Wochen-Spanne:
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Firmenname
Prelude Therapeutics Inc
Sektor
Branche
Telefon
(302) 467-1280
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Vergleichen Sie PRLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.65 | 106.87M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Eingeleitet | Jefferies | Buy |
| 2022-03-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-28 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2020-11-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
| 2020-10-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Prelude Therapeutics divulges new JAK2 inhibitors - BioWorld MedTech
It makes sense and dollars to buy Prelude Therapeutics Inc (PRLD) stock - Setenews
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Prelude Therapeutics (PRLD) Reveals Promising Preclinical Data a - GuruFocus
Prelude Therapeutics (Nasdaq: PRLD) details MPN pipeline at 2025 ASH, eyes 2026 IND - Stock Titan
What insider trading reveals about Prelude Therapeutics Incorporated stockShort Setup & Daily Volume Surge Trade Alerts - Newser
VIX Spike: How Prelude Therapeutics Incorporated stock compares to industry benchmarksJuly 2025 Decliners & Growth Focused Stock Pick Reports - moha.gov.vn
Growth Report: What dividend safety score for Prelude Therapeutics Incorporated stockJuly 2025 Big Picture & Daily Volume Surge Signals - moha.gov.vn
PRLD Investors Have Opportunity to Join Prelude - GlobeNewswire
This trade activity should not be overlooked: Prelude Therapeutics Inc (PRLD) - Setenews
Prelude Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends - Markets Mojo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics IncorporatedPRLD - PR Newswire
Will Prelude Therapeutics Incorporated stock outperform Dow Jones indexJuly 2025 Sentiment & Smart Money Movement Alerts - newser.com
Is Prelude Therapeutics Incorporated stock supported by innovation pipeline2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation ... - Bakersfield.com
Prelude Therapeutics Incorporated (PRLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What to do if you’re stuck in Prelude Therapeutics IncorporatedPortfolio Update Summary & Smart Investment Allocation Insights - newser.com
Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027 - MyChesCo
Is Prelude Therapeutics Incorporated stock ready for a breakoutJuly 2025 Sector Moves & Weekly Market Pulse Updates - newser.com
What sentiment indicators say about Prelude Therapeutics Incorporated stock2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Order flow analysis tools used on Prelude Therapeutics IncorporatedJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com
Can Prelude Therapeutics Incorporated stock hit analyst price targets2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
Real time alert setup for Prelude Therapeutics Incorporated performanceProduct Launch & Safe Entry Trade Signal Reports - newser.com
Is Prelude Therapeutics Incorporated stock supported by strong fundamentalsJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MyChesCo
Using flow based indicators on Prelude Therapeutics Incorporated2025 Market Sentiment & Fast Moving Trade Plans - newser.com
Taking on analysts’ expectations and winning: Prelude Therapeutics Inc (PRLD) - Setenews
Prelude Therapeutics’ Earnings Call Highlights Strategic Moves and Challenges - MSN
Published on: 2025-11-16 22:10:23 - newser.com
What institutional flow reveals about Prelude Therapeutics IncorporatedJuly 2025 Earnings & Safe Capital Growth Tips - newser.com
Is Prelude Therapeutics Incorporated stock a defensive play in 2025Weekly Risk Summary & Daily Oversold Bounce Ideas - newser.com
How to build a custom watchlist for Prelude Therapeutics IncorporatedJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com
Pattern recognition hints at Prelude Therapeutics Incorporated upsideSwing Trade & Advanced Technical Analysis Signals - newser.com
How moving averages guide Prelude Therapeutics Incorporated tradingBuy Signal & Weekly Breakout Watchlists - newser.com
Can Prelude Therapeutics Incorporated stock sustain free cash flow growthJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Volume spikes in Prelude Therapeutics Incorporated stock – what they meanMarket Performance Report & Daily Stock Momentum Reports - newser.com
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Q3 2025 Earnings Call Transcript - Insider Monkey
Will Prelude Therapeutics Incorporated stock deliver shareholder valueTrade Exit Summary & AI Forecast for Swing Trade Picks - newser.com
Published on: 2025-11-14 02:04:28 - newser.com
Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):